Wyeth loratadine deal
This article was originally published in The Tan Sheet
Impax Labs to supply Wyeth Consumer Healthcare with generic OTC forms of Schering-Plough's Claritin-D 12-hour, 24-hour extended release tablets, Hayward, Calif.-based firm reports June 20. "Semi-exclusive" worldwide agreement allows Impax to license products to companies other than Wyeth, demands up-front milestone payments. Deal appears to cover loratadine forms other than those sought in Wyeth's 505(b)(2) application submitted to FDA early this year (1"The Tan Sheet" Feb. 4, 2002, p. 3)...
You may also be interested in...
Schering-Plough's lawsuits against McNeil Consumer Healthcare and Whitehall-Robins could at least temporarily relieve FDA of having to make a highly charged public policy decision on whether to advocate a forced switch of second-generation antihistamines
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.